Mode
Text Size
Log in / Sign up
Phase 2 N=26 Randomized Triple-blind Treatment

Nitrites, Exercise, and Peripheral Arterial Disease

Peripheral Arterial Disease

Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Jan 2016
Primary outcome: Primary: Change in Exercise Capacity: VO2peak (Maximal Oxygen Consumption) — 1.48; 0.23 ml/kg/min

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training (Drug); Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training (Other)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Duke University
Primary completion
Nov 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Exercise Capacity: VO2peak (Maximal Oxygen Consumption)
1.48; 0.23
PRIMARY
Change In Time To Exhaustion
289.56; 254.92
SECONDARY
Change in Functional Ability
172.89; 95
SECONDARY
Change In Claudication Onset Time
199.22; 48.58
SECONDARY
Change In Vascular Function (BAFMD)
-1.14; -0.19
SECONDARY
Change in Angiogenesis
0.38; 0.26

Summary

The hypothesis of this proposal is that in subjects with PAD, regular consumption of a high nitrate supplement which raises plasma nitrite, in conjunction with 12 weeks of supervised exercise training at the limb ischemic threshold (SET) will produce a greater clinical benefit (increases in COT and PWT) than placebo plus supervised exercise at the limb ischemic threshold (PET).

Eligibility Criteria

Inclusion Criteria

  • Peripheral Arterial Disease (ABI of less than 0.9)
  • Intermittent Claudication for 3 or more months

Exclusion Criteria

  • Individuals with known alcohol or drug abuse problems
  • Individuals who have suffered a heart attack or stroke, or have changes on a resting ECG, in the last 3 months
  • Those classified as American Heart Association Class D
  • Gangrene, impending limb loss or osteomyelitis
  • Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months of enrollment
  • Severe peripheral neuropathy
  • Any condition other than PAD that limits walking
  • Chest pain during treadmill exercise which appears before the onset of claudication, or >3mm ST depression during exercise
  • Subjects taking nitrates or nitroglycerin products
  • Must not be taking protein pump inhibitor medications
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01684930). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search